PRNewswire, March 8, 2009 - A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT®, is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis. Significant efficacy differences favoring LCD solution over a 12-week treatment phase were also pronounced after treatment stopped, during a 6-week regression phase. The research, a randomized, investigator-blind, active-controlled study of 60 adults with moderate plaque psoriasis, was conducted by a team of investigators at the Clinical Unit for Research Trials in Skin (CURTIS) at Massachusetts General Hospital in Boston, MA.
The team's conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped. Its main findings include:
• LCD therapy produced a significantly better reduction in psoriasis severity than calcipotriol therapy in 12 weeks based on PASI 50 (67% vs. 36%) and PASI 75 (37% vs. 0%) achievers and percent change in PASI (58% vs 37%) and PGA scores (P<0.05).
• Significantly fewer LCD-treated patients than calcipotriol-treated patients regressed to initial disease severity within 6 weeks of stopping treatment (P<=0.005).
• PASI scores and PGA scores worsened significantly after stopping calcipotriol therapy but not after stopping LCD therapy (P<=0.05).
Within 6 weeks of completing treatment, LCD-treated patients reported better control of a range of psoriasis symptoms - including scaling/flaking, redness, skin texture, itch, overall appearance, and overall discomfort - than calcipotriol-treated patients.
Patients' rated LCD solution and calcipotriol cream as comparable for convenience, irritation potential, and aesthetic attributes (e.g., staining, scent).
Data on file, NeoStrata Company, Inc.